Azole-echinocandin Combination Therapy for Invasive Aspergillosis
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goals of this study are 3-fold:
First, the main study and the primary endpoint will evaluate if the overall mortality can be
decreased with initial azole-echinocandin combination therapy compared with triazole
monotherapy in patients with IA and documented voriconazole susceptibility.
Second, the study design described will also allow to study several other subpopulations;
Indeed, the outcome of the following subgroups will be evaluated as well; a. Patients
starting azole monotherapy but who switch to directed therapy when it has become clear that
the infection is caused by an azole resistant A. fumigatus. b. patients in which eventually
no resistance data become available in relation to the treatment they received.
Third, the study will evaluate what the outcome is of patients that turn out to be infected
with a triazole resistant A. fumigatus who started with a triazole-echinocandin combination
therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
KCE Stichting Hemato-Oncologie voor Volwassenen Nederland ZonMw: The Netherlands Organisation for Health Research and Development